EB-1020 (Centanafadine) high dose

Phase 3

OTSUKA (OTSKF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '27

OTSKFPhase 3$38.8B

EB-1020 (Centanafadine) high dose Phase 3 Est. Readout

EB-1020 (Centanafadine) high dose• Attention-Deficit Hyperactivity Disorder(ADHD)180

Aug 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Attention-Deficit Hyperactivity Disorder(ADHD)

View Full Landscape

Drug Information

Target Indication

Attention-Deficit Hyperactivity Disorder(ADHD)

Clinical Trial

NCT07086313

Last updated: 12/24/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

OTSKF

OTSUKA

Healthcare•North America•NASDAQ

Related Pipeline

Aripiprazole tablet, 10 mgPhase 3

Schizophrenia

Brexpiprazole, OPC-34712Phase 3

Agitation Associated With

Centanafadine XRPhase 3

Attention-deficit/Hyperactivity Disorder

JNT-517 TabletPhase 3

Phenylketonuria (PKU)

centanafadine capsulePhase 3

Attention Deficit/Hyperactivity Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts